CDTI invests in Integra Therapeutics, together with Invivo, Columbus, and AdBio Partners

Innvierte SICC of CDTI Innovación invests in Integra Therapeutics, together with three co-investors, to develop a gene-editing platform for the treatment of oncological, autoimmune, and genetic diseases

Integra Therapeutics is a biotechnology company creating next-generation genetic writing tools to increase the efficiency and safety of advanced therapies.

This company, a spin-off from Universitat Pompeu Fabra (UPF), was founded in 2020 by Dr. Marc Güell and Dr. Avencia Sánchez-Mejías. It has designed the FiCAT genetic writing platform to develop cell therapies for autoimmune and oncological diseases, as well as gene therapies for rare diseases.

Thanks to this technological solution, Integra Therapeutics is generating FiCAT proof-of-concept data on its first gene therapy, using systemic delivery with non-viral vectors through lipid nanoparticles (LNPs) to treat a severe pediatric liver disease.

CDTI Innovación, through Innvierte, has completed an investment in this company together with INVIVO VENTURES, FCR, COLUMBUS LIFE SCIENCES FUND III, F.C.R., and AdBio Partners AFB FUND II, for a total amount of €2.7 million. With this participation, CDTI Innovación contributes to the development of new advanced therapies to treat oncological, autoimmune, and genetic diseases.

INVIVO VENTURES, FCR

A fund managed by INVIVO PARTNERS, S.G.E.I.C, S.A., a venture capital firm specialized in early-stage healthcare companies.

Its team combines scientific, technical, and financial expertise to make impactful investments and foster growth in the healthcare sector, particularly in biotechnology companies developing innovative medicines, with a special focus on advanced therapies and synthetic biology.

COLUMBUS VENTURE PARTNERS

Columbus Venture Partners is a venture capital firm specialized in biotechnology and healthcare, founded in 2016 (Valencia) by Javier García Cogorro and Damià Tormo. With a differentiated investment model and a strong track record in supporting industrial platforms for advanced therapies, Columbus Venture Partners actively participates in the creation and growth of more than 80% of its portfolio companies. It currently manages €400 million across four funds, which have originated and/or invested in around 50 healthcare companies.

AdBio Partners AFB FUND II

A fund managed by AdBio Partners, a European venture capital firm headquartered in Paris with offices in Barcelona, investing in highly innovative projects. Its strategy combines extensive experience in company creation as well as early-stage investments, providing strong business support to drive company growth. Founded in 2016, AdBio Partners has made 28 European investments through two seed funds. These companies have raised more than €1 billion in additional capital from international syndicates and strategic funds.

Innvierte

Innvierte is an initiative aimed at promoting business innovation by supporting venture capital investment in technology-based or innovative companies. This program operates through the closed-end collective investment company Innvierte Economía Sostenible SICC S.M.E., S.A., self-managed and supervised by the Spanish National Securities Market Commission (CNMV), with CDTI Innovación as its sole shareholder.

To date, CDTI Innovación has committed €2.661 billion to 61 investment vehicles that have invested in more than 622 companies, and through its co-investment line has directly committed €723 million in 190 companies.

Innvierte is part of the Spanish Strategy for Science, Technology, and Innovation 2021–2027, approved by the Council of Ministers in September 2020. This strategy includes the objectives, reforms, and measures to be adopted across R&D&I to drive its growth and impact and is one of the pillars of the Government’s R&D&I policy for the coming years.

CDTI Innovación

The Centre for the Development of Technology and Innovation (CDTI E.P.E.) is the innovation agency of the Spanish Ministry of Science, Innovation and Universities, with the mission of promoting technological innovation in the business sector. Its mission is to ensure that Spanish companies generate and transform scientific and technical knowledge into globally competitive, sustainable, and inclusive growth. In 2024, under its new strategic plan, CDTI provided more than €2.3 billion in support to Spanish companies and startups.